FDA Approves Bimzelx for Three New Indications

THURSDAY, Sept. 26, 2024-- The U.S. Food and Drug Administration has approved Bimzelx (bimekizumab-bkzx) for the treatment of adults with active psoriatic arthritis (PsA), adults with active nonradiographic axial spondyloarthritis (nr-axSpA) with o...